• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[非医学和非技术治疗干预措施的证据基础是什么?]

[What's the evidence base for non-medical and non-technical therapeutic interventions?].

作者信息

Bertelsmann Hilke

机构信息

Fachhochschule der Diakonie, Grete Reich Weg 9, Bielefeld.

出版信息

Z Evid Fortbild Qual Gesundhwes. 2013;107(3):208-13. doi: 10.1016/j.zefq.2013.04.005. Epub 2013 May 27.

DOI:10.1016/j.zefq.2013.04.005
PMID:23790695
Abstract

Health-related interventions that do not include drugs or technical procedures have not appeared very often in the German Federal Joint Committee's (GBA) evidence-based decision making process over the last years. In this regard the GBA has so far never given any instructions to the Institute for Quality and Efficiency in Health Care (IQWiG). The level of evidence for these methods is often limited by the lack of randomised controlled trials. The available studies often show a high risk of bias because of poor planning, processing and reporting as well as lack of blinding. External validity is often limited by use of a standardised monotherapy in the study, but a mix of different, individualised methods in the field. Another common problem is the lack of patient-related, long-term outcome variables. Further research is needed to develop methods for high-quality trials and evidence-based assessments in the area of non-medical, non-technical therapeutic interventions. (As supplied by publisher).

摘要

在过去几年中,不涉及药物或技术程序的健康相关干预措施在德国联邦联合委员会(GBA)基于证据的决策过程中并不常见。在这方面,GBA迄今为止从未向医疗质量与效率研究所(IQWiG)发出过任何指令。由于缺乏随机对照试验,这些方法的证据水平往往受到限制。现有研究由于规划、实施和报告不佳以及缺乏盲法,常常显示出较高的偏倚风险。外部有效性通常因研究中使用标准化单一疗法而受到限制,而该领域实际采用的是多种不同的个体化方法。另一个常见问题是缺乏与患者相关的长期结局变量。需要进一步开展研究,以开发非医学、非技术治疗干预领域高质量试验和基于证据评估的方法。(由出版商提供)

相似文献

1
[What's the evidence base for non-medical and non-technical therapeutic interventions?].[非医学和非技术治疗干预措施的证据基础是什么?]
Z Evid Fortbild Qual Gesundhwes. 2013;107(3):208-13. doi: 10.1016/j.zefq.2013.04.005. Epub 2013 May 27.
2
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
3
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
4
[The role of non-pharmaceutical and non-technical therapeutic interventions in patient care].[非药物和非技术治疗干预措施在患者护理中的作用]
Z Evid Fortbild Qual Gesundhwes. 2013;107(3):200-5. doi: 10.1016/j.zefq.2013.04.008. Epub 2013 May 23.
5
Methodological idiosyncracies, frameworks and challenges of non-pharmaceutical and non-technical treatment interventions.非药物及非技术治疗干预措施的方法特性、框架与挑战
Z Evid Fortbild Qual Gesundhwes. 2013;107(3):214-20. doi: 10.1016/j.zefq.2013.05.002. Epub 2013 May 21.
6
[Inpatient medical rehabilitation in diabetes mellitus in light of evidence based practice guidelines: an evaluation on the basis of BfA routine data].基于循证实践指南的糖尿病住院医疗康复:基于德国法定健康保险机构常规数据的评估
Rehabilitation (Stuttg). 2003 Apr;42(2):94-108. doi: 10.1055/s-2003-38812.
7
[Closing evidence gaps].[填补证据空白]
Z Evid Fortbild Qual Gesundhwes. 2011;105(9):652-6. doi: 10.1016/j.zefq.2011.10.004. Epub 2011 Nov 9.
8
[Developing evidence based guidelines on cardiac rehabilitation - phase 1: a qualitative review].[制定基于证据的心脏康复指南——第1阶段:定性综述]
Rehabilitation (Stuttg). 2002 Aug;41(4):226-36. doi: 10.1055/s-2002-33267.
9
[The significance of clinical guidelines for rehabilitation].[临床康复指南的意义]
Rehabilitation (Stuttg). 2003 Apr;42(2):67-73. doi: 10.1055/s-2003-38814.
10
Conquering the intolerable burden of malaria: what's new, what's needed: a summary.战胜疟疾的沉重负担:新进展与需求总结
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15.